S2 Ep 6 | Good Science Will Find Funding: Venture Lending, Exits, And Building Talent In Life Sciences copertina

S2 Ep 6 | Good Science Will Find Funding: Venture Lending, Exits, And Building Talent In Life Sciences

S2 Ep 6 | Good Science Will Find Funding: Venture Lending, Exits, And Building Talent In Life Sciences

Ascolta gratuitamente

Vedi i dettagli del titolo

A proposito di questo titolo

 WELCOME TO VITALS, THE PULSE OF GEORGIA LIFE SCIENCESIn this incredible, timely, and informative episode of VITALS, Maria Thacker Goethe, the CEO of Georgia Life Sciences, interviews Scott McCarty, Managing Director of Sales, Origination, Healthcare and Life Sciences at Silicon Valley Bank, who discusses venture debt strategy, cautious optimism in today’s market cycle, robust biotech exits, and how executives can scale healthcare innovation, medtech, and health tech companies across Georgia and the broader Southeast ecosystem.Scott McCarty's Career JourneyMaria Thacker Goethe asks Scott McCarty about his career journey, starting with his background in finance at UGA and his initial aversion to commercial banking.Scott shares his experience of joining Silicon Valley Bank (SVB) through a friend, finding it more entrepreneurial and less stodgy than traditional banks.Scott describes the growth of SVB, from a regional bank to a significant player with $230 billion in total assets before merging with First Citizens.Scott emphasizes SVB's continued focus on venture debt and healthcare innovation, despite the bank's expansion and changes.SVB's Role in Venture Lending and Healthcare InnovationMaria inquires about SVB's current structure and its role in venture lending and healthcare innovation.Scott explains that SVB is still a major player in venture lending, particularly in the healthcare innovation space.Scott discusses the evolution of SVB's healthcare and life sciences business, which has become a significant growth engine for the bank.Scott notes the increased competition in the market, with many former SVB colleagues starting new ventures, but maintains that SVB remains a friendly competitor.Scott McCarty's Current Role and ResponsibilitiesMaria asks about Scott McCarty's current role and responsibilities.Scott describes his initial role in starting a team in the mid-Atlantic and southeast, covering from Philadelphia to Miami.Scott explains the evolution of his role into a national sales role, working with all eight of SVB's teams and focusing on growth-stage companies.Scott highlights the shift in Series A funding, with larger Series A rounds now common in the biotech space.Georgia's Life Sciences Ecosystem and Personal BackgroundMaria asks about Scott's personal background and his time in Georgia.Scott shares his history of moving frequently due to his father's job at IBM, eventually settling in Georgia.Scott mentions his high school experience at Chattahoochee High School, part of the first graduating class.Maria and Scott discuss the evolution of company building over the past 20 years, noting the shift towards more virtual companies and the challenges of retaining local talent.Market Outlook for 2026 and JPM Healthcare WeekMaria asks about the market outlook for 2026 and the impact of the upcoming JPM Healthcare Week.Scott expresses cautious optimism, noting the low fundraising environment of the past few years and the need for high-end announcements at JPM.Scott discusses the importance of maintaining a robust exit environment to keep the market healthy.Scott highlights the role of AI in healthcare innovation, particularly in drug discovery and data analysis, and its potential to drive investment.Challenges for Early-Stage Companies and Strategic AdviceMaria asks for advice for early-stage companies struggling to raise capital.Scott emphasizes the importance of surrounding oneself with good advisors and having a strong story to tell.Scott advises early-stage entrepreneurs to be receptive to feedback and to leverage conferences and networking opportunities.Scott discusses the role of family offices and private high net worth offices in funding early-stage companies and the challenges of accessing these funds.Investment and Exit Themes for the Next 12-24 MonthsMaria inquires about major investment and exit themes for the next 12-24 months.Scott notes the continued importance of venture fundraising, despite the current low levels, and the role of established funds in deploying capital.Scott highlights the importance of maintaining a robust exit environment, with a focus on mid-range exits in addition to the large ones.Scott discusses the role of AI in healthcare innovation and its potential to drive investment and growth.Venture Debt and Capital StrategyMaria asks about the role of venture debt and capital strategy in the industry.Scott explains the importance of using venture debt alongside equity to extend cash runway and achieve higher valuations.Scott discusses the competitive landscape for venture debt, with both banks and debt funds vying for market share.Scott emphasizes the importance of selecting the right capital partner, one that offers sector expertise and a strong network.Georgia's Life Sciences Ecosystem and Future GrowthMaira asks about the current state of Georgia's life sciences ecosystem and its future growth potential.Scott notes the maturation of the ecosystem, with a focus on ...
Ancora nessuna recensione